STING1 and neoplasm: Following our in vitro findings that B16‐F10 cells synergistically increased proinflammatory cytokine release, we sought to assess the therapeutic benefit of combining VPS34i SB02024 with STING agonist ADU‐S100 in B16‐F10 tumor‐bearing mice.